Skip to main content
. 2016 Apr 6;7:11190. doi: 10.1038/ncomms11190

Figure 2. BCL-W and BCL-XL maintain the viability of senescent cells.

Figure 2

(a) IMR-90 human fibroblasts (DIS, and OIS cells, as well as control G or V cells) were treated for 24 h with the indicated concentrations of Obatoclax or with vehicle (DMSO). Cell survival relative to vehicle-treated cells was determined by quantification of the remaining adherent cells. Histograms indicate the percentages of surviving senescent (DIS and OIS) cells compared with G or V controls. Data are presented as mean±s.e.m of three repeats, performed in triplicates. (b) Percentage survival of the cells described in a following 24 h treatment with the indicated concentrations of the BCL-2 inhibitor ABT-199 and of SH-SY5Y cells, which express high BCL-2 levels and serve as positive control for response to the drug. Data are presented as mean±s.e.m of three repeats, performed in triplicates. (c) Percentage survival of DIS cells transduced with siRNAs targeting BCL-2, BCL-W and BCL-XL or their combinations as indicated. (d) Western blot analysis of BCL-2, BCL-W and BCL-XL following siRNA treatment of DIS cells. (e) Percentage survival of DIS cells transduced with siRNAs targeting BCL-W, BCL-XL or both, with or without treatment with the BCL-2 inhibitor ABT-199 (10 μM). Data are presented as mean±s.e.m of three repeats, performed in triplicates. Data were analysed using Student's t-test. *P<0.05, **P<0.005, ***P<0.0005.